

Genetic Testing for *FMR1* Mutations

Policy Number: AHS – M2028	Prior Policy Name and Number, as applicable: N/A
Initial Effective Date: June 1, 2023	Current Effective Date: June 1, 2023
Line(s) of Business: HMO; PPO; QUEST Integration; Medicare; FEP	Precertification: Required

I. Policy Description

Fragile X syndrome (FXS) is an X-linked disorder resulting from a loss of function mutation of the Fragile X Mental Retardation-1 (*FMR1*) gene; FXS is the most common cause of heritable intellectual disability. *FMR1*-related disorders include FXS, fragile X-associated tremor/ataxia syndrome (FXTAS), and *FMR1*-related primary ovarian insufficiency (FRPOI). FXS results in a range of physical, cognitive, and behavioral effects of variable severity, generally characterized by moderate intellectual disability and autistic characteristics in affected males and mild intellectual disability and emotional and/or psychiatric problems in affected females.

II. Indications and/or Limitations of Coverage

Application of coverage criteria is dependent upon an individual's benefit coverage at the time of the request. Specifications pertaining to Medicare and Medicaid can be found in Section VII of this policy document

- 1) Pre- and post-test genetic counseling **MEETS COVERAGE CRITERIA** for individuals undergoing *FMR1* gene testing.
- 2) Diagnostic genetic testing for *FMR1* gene CGG repeats and methylation status **MEETS COVERAGE CRITERIA** for:
 - a) Males and females with unexplained mental retardation, developmental delay, or autism spectrum disorder, *OR*
 - b) Symptomatic individuals with features of Fragile X syndrome or a family history of Fragile X syndrome, *OR*
 - c) Females with unexplained ovarian insufficiency, unexplained ovarian failure, or unexplained elevated FSH prior to age 40, *OR*
 - d) Individuals with unexplained late-onset tremor-ataxia, *OR*
 - e) Fetuses and offspring of known *FMR1* premutation or full mutation carriers
- 3) Carrier screening for *FMR1* gene CGG repeat length **MEETS COVERAGE CRITERIA** for individuals seeking pre-conception or prenatal care.
- 4) Genetic screening for *FMR1* gene CGG repeat length more than once per lifetime **DOES NOT MEET COVERAGE CRITERIA**
- 5) Determination of *FMR1* gene point mutations **DOES NOT MEET COVERAGE CRITERIA**.
- 6) Determination of *FMR1* gene deletion **DOES NOT MEET COVERAGE CRITERIA**.

- 7) Population screening for Fragile X syndrome **DOES NOT MEET COVERAGE CRITERIA.**
- 8) Cytogenetic testing for Fragile X syndrome **DOES NOT MEET COVERAGE CRITERIA.**
- 9) Testing for the FMRP protein **DOES NOT MEET COVERAGE CRITERIA.**

III. Table of Terminology

Term	Definition
ACMG	American College of Medical Genetics and Genomics
ACOG	The American College of Obstetricians and Gynecologists
CCMG	Canadian College of Medical Geneticists
CI	Confidence interval
CLIA '88	Clinical Laboratory Improvement Amendments of 1988
CMS	Centers for Medicare and Medicaid
CNS	Central nervous system
DBS	Dried blood spots
dTP-PCR	Triplet-primed polymerase chain reaction
EMQN	European Molecular Genetics Quality Network
FDA	Food and Drug Administration
<i>FMR1</i>	<i>Fragile X mental retardation-1</i>
FMRP	Protein encoded by <i>Fragile X mental retardation-1</i>
FRPOI	<i>Fragile X mental retardation-1</i> -Related Primary Ovarian Insufficiency
FSH	Follicle stimulating hormone
FXS	Fragile X syndrome
FXTAS	Fragile X-associated tremor/ataxia syndrome
LDT	Laboratory-developed test
mGluR	Metabotropic glutamate receptor 2
mRNA	Messenger ribonucleic acid
miRNA	Micro ribonucleic acid
MoMe	Methylation mosaic
MoMN	Mosaicism for full mutation and normal alleles
MoMP	Mosaic premutation and full mutation
mRNA	Messenger ribonucleic acid
NORD	National Organization for Rare Disorders\
PCR	Polymerase chain reaction
RNA	Ribonucleic acid
SB	Southern blotting
SNP	Single nucleotide polymorphisms
SOGC	Society of Obstetricians and Gynecologists of Canada

IV. Scientific Background

Fragile X Syndrome (FXS) and related disorders affects about one in 4,000 males and one in 6,000 to 8,000 females in America. Transmitted as an X-linked dominant trait with reduced penetrance, FXS is

associated with a fragile site on the X chromosome identified as the *Fragile X Mental Retardation-1* (*FMR1*) gene. More than 99% of patients with FXS have a mutation in this gene with over 200 CGG repeats and atypical methylation. The protein encoded by *FMR1* (FMRP) is a multifunctional RNA-binding protein that regulates the translation of a subset of dendritic mRNAs and plays a central role in neuronal development and synaptic plasticity.

The absence of FMRP results in excessive and persistent mGluR-mediated protein synthesis in postsynaptic dendrites, dysregulation of ion homeostasis, and disruption of calcium ion homeostasis leading to abnormal synaptic signaling and dendritic development. The typical clinical phenotype includes intellectual disability, social impairment, autism spectrum disorder, speech and language delay, neurological dysfunction (seizures and abnormal sleep patterns), sensory hypersensitivity, and a characteristic physical appearance that typically develops in the second decade of life. Autism disorders are seen in approximately one third of FXS patients, affecting males more frequently than females. Between 55 and 90% of patients with autism and FXS report gaze aversion, hand flapping, repetitive behaviors, reduced social interaction, anxiety, speech preservations, and aggressive behaviors.

Any genetic alteration that results in a lack of functional FMRP can cause FXS symptoms. The most common type of mutation of *FMR1* is the expansion of a CGG trinucleotide repeat in the 5' untranslated region of the gene. Normally, this ranges in size from 7 to about 60 repeats, with 30 being most common. The full mutation consists of expansions of over 200 repeats which become abnormally hypermethylated, silencing the *FMR1* gene and expression of FMRP. Molecular clinical correlations have shown that the resulting phenotype is related to the degree of methylation and mosaicism rather than the number of repeats.

Alleles with 55 to 200 CGG repeats are generally unmethylated with normal transcript and FMRP level; however, they are extremely unstable during transmission to the next generation and are referred to as premutations. Although premutation carriers produce normal levels of FMRP, mRNA levels are elevated, causing toxic effects such as protein sequestration and mitochondrial dysfunction. As a consequence, RNA toxicity leads to neuronal toxicity and a spectrum of pre-mutation associated disorders such as primary ovarian insufficiency (FXPOI) and tremor ataxia syndrome (FXTAS). An increased frequency of neurological, psychological, endocrine, and immune-related characteristics has been documented in premutation carriers. Those with the premutation have higher rates of anxiety, depression, autistic traits, and physical health symptoms such as chronic fatigue and pain, fibromyalgia, and sleep disorders.

Analytical Validity

While many fragile X testing methods have been developed, no single approach can characterize all aspects of *FMR1* mutations and expansions, especially when mosaicism is taken into consideration. In a diagnostic setting, it is important to not only detect presence of the CGG expansion, but to also determine its size and methylation status. Molecular diagnostic testing of *FMR1* currently relies on a combination of polymerase chain reaction (PCR) and Southern blot (the gold standard) for the CGG-repeat expansion and methylation analyses. Detection of rare point mutations and deletions requires sequence analysis. This has limited the ability to implement any type of population screening.

CGG repeat-primed PCR designed to detect the full range of fragile X expanded alleles followed by analysis via capillary electrophoresis and melt curve techniques minimizes the need for Southern blot analysis. The FastFraX *FMR1* test was evaluated in 198 archived clinical samples, yielding results of 100% sensitivity (95% CI, 91.03% to 100%) and 100% specificity (95% CI, 97.64% to 100%) in categorizing patient samples into the respective normal, intermediate, premutation, and full mutation genotypes.

The triplet-primed PCR method (dTP-PCR) has been validated by comparison to Southern blot analysis for use in determining mutations in the *FMR1* gene; clinical performance was confirmed with 40 samples resulting in 100% sensitivity and 90.48% specificity in the detection of CGG repeats greater than 30. This testing method may be utilized to screen a general population by quickly determining specific allelic changes in the *FMR1* gene.

Immunohistochemical detection of FMRP has been validated in lymphocytes and chorionic villi samples as an alternative prenatal diagnostic method for detection of full mutations in male fetuses; however, staining is more complex in female fetuses due to X-inactivation and is insufficient for diagnostic use. Clinical and analytical specificity and sensitivity of cytogenetic analysis for FXS are both insufficient.

In a retrospective design, Ramos et al. (2020) studied the performance of the commercial FragileEase PCR kit for FXS diagnosis and compared it to Southern blotting (SB), PCR, and AmpliX *FMR1* PCR. Ninety DNA samples were analyzed using FragileEase from patients with a clinical suspicion of FXS or a family history and was compared with the results from the other methods. Overall, FragileEase PCR kit had high concordance with the results from PCR, SB, and AmpliX. FragileEase was able to detect normal, intermediate/gray zone, premutation, and full mutation alleles along with female homozygosity and mosaicism. The authors conclude that "FragileEase™ PCR, as well as other commercially available kits, efficiently detect *FMR1* mutations and simplify the workflow in laboratories that performing FXS diagnoses."

Clinical Utility and Validity

As the clinical phenotype of FMR-related diseases can be subtle, its detection, especially in the prepubertal period, can be difficult. Although phenotypic symptoms are not obvious at birth, both animal and neuroimaging studies suggest that the effects of FXS begin in the prenatal period. Families report significant delays in diagnosis of FXS with 24% of families reporting that they had seen a healthcare provider more than 10 times before testing. On average, caregivers or other individuals first report concern in regard to the child's development by 13 months; however, professional confirmation of a developmental delay did not occur until an average age of 21 months, and the FXS diagnosis did not occur until an average age of nearly 32 months. Meanwhile, many families had additional children with FXS before becoming aware of the reproductive risk. Establishing a diagnosis of FXS allows for an understanding of the disorder and education on appropriate management strategies. Psychopharmacologic intervention to modify behavioral problems, such as attentional deficits, impulse control, anxiety, and emotional lability in a child with FXS can be important in addition to speech therapy, occupational therapy, special educational services, and behavioral interventions. A recent pilot of allopregnanolone in six males with FXTAS showed significant improvement in GABA metabolism, oxidative stress, and some of the mitochondria-related outcomes.

Huang et al. (2019) utilized a GC-rich PCR method to detect *FMR1* gene mutations in 30 pregnant women who were known carriers of *FMR1* mutations or who contained *FMR1* gene deletion mosaicism; samples utilized chorionic villus, amniotic fluid, or umbilical blood samples. Southern blotting was used as a confirmatory measure. PCR results showed that 18 fetuses were normal, while others presented with full *FMR1* gene mutations, premutations, and/or mosaicism. Even with successful results, the authors state that the use of a single detection method may not be sufficient in determining *FMR1* genetic mutations.

Lee et al. (2020) utilized a customized PCR and software system to detect the *FMR1* gene expansions from dried blood spots (DBS) and performed analytical validity studies to determine its accuracy,

specificity, sensitivity, and precision to be used for newborn screening. The study investigated 963 newborn dried blood spots, which were studied by DNA extraction, *FMR1* PCR amplification, and capillary electrophoresis for automated CGG repeat analysis. While previous *FMR1* newborn screening assays were unsuitable for a routine laboratory setting, this fit-for-purpose *FMR1* screening method provides a reliable method for newborn screening that is both cost-effective and compatible with simple DBS elution methods already used in newborn screening laboratories. From the 963 DBS samples tested, 957 samples (99.4%) samples were classified as normal and 6 samples (0.6%) had premutation alleles with 55-76 CGG repeat expansions. Five out of the six premutation samples had one normal allele in addition to the premutation allele, while one out of the six had only one allele. Accuracy testing results were 100% concordance with reference genotypes with no false positive or false negative test results found. CGG expansions were consistently within six CGG repeats for larger expansions up to 200, within three CGG repeats for expansions up to 137, and within a single repeat for CGG expansions less than 80. However, the authors wrote that “further studies are required to identify if early screening of Fragile X syndrome would lead to better outcomes for the children, families, and society.”

Approximately twenty individuals have been reported with rare missense or nonsense mutations in the *FMR1* gene; also reported were other coding disturbances of the same gene resulting in physical, cognitive, and behavioral features similarly seen in FXS. Studies of other *FMR* mutations that can affect the level and function of the protein include analysis of SNPs showing that 31.66 % of the *FMR1* gene SNPs were disease-related and that 50% of SNPs from online databases had a pathogenic effect. Screening of 508 males with clinical signs of mental retardation and developmental delay, but without CGG and GCC repeat expansions in the *FMR1* gene, revealed two missense mutations in the *FMR1* gene that would have not been diagnosed with standard molecular testing for FXS.

Cao et al. (2021) studied the clinical utility of screening *FMR1* gene mutations during early and middle pregnancy for those carrying high-risk CGG trinucleotide expansions. DNA samples from 316 pregnant women at 12-21 gestational weeks were collected and analyzed for CGG repeats using fluorescence PCR and capillary electrophoresis. The carrier rate of CGG repeats was 1 in 178 for the intermediate type and 1 in 772 for the premutation types. The highest frequency allele of CGG was 29 repeats, which accounted for 49.29%, followed by 30 repeats (28.56%) and 36 repeats (8.83%). In one case of a premutation type of CGG expansion, the couple chose to terminate the pregnancy. The authors conclude that “pregnant women should be screened for *FMR1* gene mutations during early and middle pregnancy, and those with high-risk CGG expansions should undergo prenatal diagnosis, genetic counseling and family study.” Ramos et al. (2021) conducted a cross-sectional study on *FMR1* gene mutations in 52 Brazilian women diagnosed with primary ovarian insufficiency. The authors extracted genomic DNA and used FragileEase PCR kits to analyze CGG trinucleotide repeat expansions in the *FMR1* gene. In total, 3.8% of participants had *FMR1* mutations. The authors further concluded that “the most frequent CGG-repeat sizes were 28 and 30.”

V. Guidelines and Recommendations

American College of Medical Genetics and Genomics (ACMG)

The American College of Medical Genetics and Genomics (ACMG) recommends FXS molecular genetic testing for:

“Fragile X syndrome:

- Individuals of either sex with mental retardation, developmental delay, or autism, especially if they have (a) any physical or behavioral characteristics of fragile X syndrome, (b) a family history of fragile X syndrome, or (c) male or female relatives with undiagnosed mental retardation.
- Individuals seeking reproductive counseling who have (a) a family history of fragile X syndrome or (b) a family history of undiagnosed mental retardation.
- Fetuses of known carrier mothers.
- Affected individuals or their relatives in the context of a positive cytogenetic fragile X test result who are seeking further counseling related to the risk of carrier status among themselves or their relatives. The cytogenetic test was used prior to the identification of the FMR1 gene and is significantly less accurate than the current DNA test. DNA testing on such individuals is warranted to accurately identify premutation carriers and to distinguish premutation from full mutation carrier women.

Ovarian dysfunction:

- Women who are experiencing reproductive or fertility problems associated with elevated follicle stimulating hormone (FSH) levels, especially if they have (a) a family history of premature ovarian failure, (b) a family history of fragile X syndrome, or (c) male or female relatives with undiagnosed mental retardation.

Tremor/ataxia syndrome:

- Men and women who are experiencing late onset intention tremor and cerebellar ataxia of unknown origin, especially if they have (a) a family history of movement disorders, (b) a family history of fragile X syndrome, or (c) male or female relatives with undiagnosed mental retardation.”

The 2013 ACMG Fragile X testing standards and guidelines, with the American Congress of Obstetricians and Gynecologists, published the following indications for fragile X diagnostic testing and carrier detection:

- “The identification of a full mutation in a male is considered diagnostic rather than predictive, inasmuch as penetrance of fragile X syndrome is virtually 100% in males and the age of onset is not variable
- The identification of a full mutation in a female may be diagnostic, but [over] 50% of females with full mutations have intellectual disability. They may, however, have some manifestations of the disease such as avoidance personality, mood, or stereotypic disorders. Nonrandom X inactivation may explain the milder phenotype in females, although the extent of symptoms cannot be determined by X-inactivation patterns from diagnostic tests that determine the expansion and methylation in blood.
- The identification of a premutation in an asymptomatic male or female undergoing carrier testing (e.g., due to a family history of intellectual disability) is predictive because FXPOI and FXTAS are not fully penetrant and are dependent on both age and allele size.
- Population carrier screening and newborn screening for fragile X syndrome are not recommended at this time and should occur only under a research protocol.
- All positive results should state that genetic counseling is recommended and testing is available for at-risk family members.”

ACMG does not recommend general population carrier screening.

In 2021, ACMG released an updated guideline for screening for autosomal recessive and X-linked conditions during pregnancy and preconception. Their practice resource aims to recommend “a consistent and equitable approach for offering carrier screening to all individuals during pregnancy and preconception” and replaces any earlier ACMG position statements on prenatal/preconception expanded carrier screening and provide the following recommendations:

- “Carrier screening enables those screened to consider their reproductive risks, reproductive options, and to make informed decisions.”
- “The phrase “expanded carrier screening” be replaced by “carrier screening”.”
- “Adopting a more precise tiered system based on carrier frequency:
 - Tier 4: <1/200 carrier frequency (includes Tier 3) genes/condition will vary by lab
 - Tier 3: $\geq 1/200$ carrier frequency (includes Tier 2) includes X-linked conditions
 - Tier 2: $\geq 1/100$ carrier frequency (includes Tier 1)
 - Tier 1: CF [Cystic Fibrosis] + SMA [spinal muscular atrophy] + Risk Based Screening
 - “Tier 1 screening conveys the recommendations previously adopted by ACMG and ACOG” and “adopts an ethnic and population neutral approach when screening for cystic fibrosis and spinal muscular atrophy. Beyond these two conditions, additional carrier screening is determined after risk assessment, which incorporates personal medical and family history as well as laboratory and imaging information where appropriate”
 - “Tier 2 carrier screening stems from an ACOG recommendation for conditions that have a severe or moderate phenotype and a carrier frequency of at least 1/100.” However, “data demonstrate that carrier screening for two common conditions using a carrier frequency threshold of 1/100 may not be equitable across diverse populations. Others have shown that limiting the carrier frequency to $\geq 1/100$ creates missed opportunities to identify couples at risk for serious conditions.”

- “We define Tier 3 screening as carrier screening for conditions with a carrier frequency $\geq 1/200$. . . Tier 2 and Tier 3 screening prioritize carrier frequency as a way to think about conditions most appropriate for screening in the general population. However, when ACOG proposed this level, they did not specify whether it was thinking about carrier frequency in terms of the global population or subpopulations. We use “carrier frequency” to mean in any ethnic group with reasonable representation in the United States.”
- “Tier 4 includes genes less common than those in Tier 3 and can identify additional at-risk couples. Tier 4 has no lower limit carrier screening frequency and can greatly extend the number of conditions screened . . . the clinical validity at this level of carrier screening may be less compelling, therefore we suggest reserving this level of screening for consanguineous pregnancies (second cousins or closer) and in couples where family or medical history suggests Tier 4 screening might be beneficial . . . Importantly, patients should understand that their chance of being a carrier for one or more conditions increases as the number of conditions screened is increased.”
- “All pregnant patients and those planning a pregnancy should be offered Tier 3 carrier screening.
- Tier 4 screening should be considered:
 - When a pregnancy stems from a known or possible consanguineous relationship (second cousins or closer);
 - When a family or personal medical history warrants.
- ACMG does NOT recommend:
 - Offering Tier 1 and/or Tier 2 screening, because these do not provide equitable evaluation of all racial/ethnic groups.
 - Routine offering of Tier 4 panels.
- “Carrier screening paradigms should be ethnic and population neutral and more inclusive of diverse populations to promote equity and inclusion.”
- “All pregnant patients and those planning a pregnancy should be offered Tier 3 carrier screening for ... X-linked (Table 6) conditions.”
- “All XX patients should be offered screening for only those X-linked genes listed in Table 6 as part of Tier 3 screening.”
- “When Tier 1 or Tier 2 carrier screening was performed in a prior pregnancy, Tier 3 screening should be offered.”

Table 6. X-linked genes recommended for carrier screening.

OMIM gene	OMIM gene name	OMIM phenotype	Phenotype
300371	<i>ABCD1</i>	300100	Adrenoleukodystrophy (ALD)
300806	<i>AFF2</i>	309548	Mental retardation, X-linked, associated with fragile site FRAXE
300382	<i>ARX</i>	308350	Developmental and epileptic encephalopathy 1 (DEE1)
300377	<i>DMD</i>	300376	Muscular dystrophy, Becker type (BMD)
		310200	Muscular dystrophy, Duchenne type (DMD)
306700	<i>F8</i>	300841	Hemophilia A (HEMA)
300746	<i>F9</i>	306900	Hemophilia B (HEMB)
309550	<i>FMR1</i>	300624	Fragile X syndrome (FXS)
300644	<i>GLA</i>	301500	Fabry disease
308840	<i>L1CAM</i>	307000	Hydrocephalus due to congenital stenosis of aqueduct of Sylvius (HSAS)
300552	<i>MID1</i>	300000	Opitz GBBB syndrome, type I (GBBB1)
300473	<i>NR0B1</i>	300200	Adrenal hypoplasia, congenital (AHC)
300461	<i>OTC</i>	311250	Ornithine transcarbamylase deficiency
300401	<i>PLP1</i>	312920	Spastic paraplegia 2, X-linked (SPG2)
312610	<i>RPGR</i>	300029	Retinitis pigmentosa 3 (RP3; RP)
		300455	Retinitis pigmentosa, X-linked, and sinorespiratory
		300834	Infections, with or without deafness
			Macular degeneration, X-linked atrophic
300839	<i>RS1</i>	312700	Retinoschisis 1, X-linked, juvenile (RS1)
300036	<i>SLC6A8</i>	300352	Cerebral creatine deficiency syndrome 1 (CCDS1)

OMIM Online Mendelian Inheritance in Man.⁵⁵

The American College of Obstetricians and Gynecologists (ACOG)

The American College of Obstetricians and Gynecologists (ACOG) published committee opinion 691 which recommends Fragile X premutation carrier screening for women with a family history of fragile X-related disorders or intellectual disability suggestive of fragile X syndrome and who are considering pregnancy or are currently pregnant.

If a woman has unexplained ovarian insufficiency or failure or an elevated follicle-stimulating hormone level before age 40 years, fragile X carrier screening is recommended to determine whether she has an *FMR1* premutation.

All identified individuals with intermediate results and carriers of a fragile X premutation or full mutation should be provided follow-up genetic counseling to discuss the risk to their offspring of inheriting an expanded full-mutation fragile X allele and to discuss fragile X-associated disorders (premature ovarian insufficiency and fragile X tremor/ataxia syndrome).

Prenatal diagnostic testing for FXS should be offered to known carriers of the fragile X premutation or full mutation.

This guideline was reaffirmed in 2020.

Society of Obstetricians and Gynecologists of Canada (SOGC) and Canadian College of Medical Geneticists (CCMG) Guidelines

Guidelines for FXS genetic testing were given in a joint statement from the SOGC and CCMG. It is stated that “Any woman with a personal or family history of Fragile X- or Fragile X mental retardation 1–related disorders; unexplained intellectual disability or developmental delay; autism; ovarian insufficiency with elevated follicle stimulating hormone at age < 40 years of unknown etiology; or any woman with a family history of male relatives with developmental delay, autism, or isolated cerebellar ataxia and tremor should be offered screening for this condition (II-2A) (GRADE moderate/moderate).” It is also stated that “Population carrier screening for Fragile X syndrome in all women of reproductive age cannot be recommended at this time (II-2D) (GRADE moderate/moderate)” and “Fragile X carrier testing must only occur after detailed genetic counselling and informed consent from the woman to be tested has been obtained (III-A) (GRADE low/moderate).”

National Society of Genetic Counselors (NSGC)

The National Society of Genetic Counselors published guidelines which recommend: “Centers offering population screening should ensure that they have the resources available to provide pre- and post-test genetic counseling that supports the psychosocial and clinical needs of the patient and family. In light of widespread *FMR1* testing among women without known risk factors, genetic counselors should anticipate seeing patients who did not receive any pre-test information, have no prior knowledge of *FMR1*-associated disorders, and are unprepared to learn that they have an *FMR1* mutation. Prenatal diagnosis should be offered to women with pre- or full mutations. Males with premutation alleles should receive genetic counseling about potential phenotypic risks to their daughters, all of whom will inherit premutations.”

American Academy of Pediatrics Committee on Genetics (AAP)

The American Academy of Pediatrics recommends testing for FXS in children with any of the following, particularly when associated with physical and behavioral characteristics of FXS or a relative with undiagnosed intellectual disability: developmental delay, borderline intellectual abilities or intellectual disability, or diagnosis of autism without a specific etiology.

European Molecular Genetics Quality Network (EMQN)

The EMQN published their best practice guidelines concerning FXS and fragile X-associated disorders in 2015. They state, “Prenatal testing is not indicated for the pregnant partner of a male with a premutation.” but they do recommend offering prenatal diagnosis to any woman with 55 or more CGG repeats; “Prenatal testing may be considered for a female fetus of a full mutation father as a cautionary measure (full mutation or MoMP [mosaic premutation and full mutation] or MoMe [methylation mosaic]).” Concerning molecular diagnostic analysis in FXS and fragile X-associated disorders, they state the following:

“It is best practice to use a method which detects the whole range of expansions when testing relatives (including prenatal diagnosis) in a family with any known fragile X disorder due to expansion. When testing the *FMR1* gene in population screening, the report must specify that rare cases of point mutation or deletion cannot be detected, nor rare cases of CGG expansion mosaicism (MoMN) if the method used cannot detect the whole range of expansions. It could be useful to confirm results by an independent method when detecting an expansion in an index case depending on specific pitfalls of each method.”

VI. Applicable State and Federal Regulations

DISCLAIMER: If there is a conflict between this Policy and any relevant, applicable government policy for a particular member [e.g., Local Coverage Determinations (LCDs) or National Coverage Determinations (NCDs) for Medicare and/or state coverage for Medicaid], then the government policy will be used to make the determination. For the most up-to-date Medicare policies and coverage, please visit the Medicare search website: <http://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx>. For the most up-to-date Medicaid policies and coverage, visit the applicable state Medicaid website.

Food and Drug Administration (FDA)

Many labs have developed specific tests that they must validate and perform in house. These laboratory-developed tests (LDTs) are regulated by the Centers for Medicare and Medicaid (CMS) as high-complexity tests under the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88). LDTs are not approved or cleared by the U. S. Food and Drug Administration; however, FDA clearance or approval is not currently required for clinical use.

VII. Important Reminder

The purpose of this Medical Policy is to provide a guide to coverage. This Medical Policy is not intended to dictate to providers how to practice medicine. Nothing in this Medical Policy is intended to discourage or prohibit providing other medical advice or treatment deemed appropriate by the treating physician.

Benefit determinations are subject to applicable member contract language. To the extent there are any conflicts between these guidelines and the contract language, the contract language will control.

This Medical Policy has been developed through consideration of the medical necessity criteria under Hawaii's Patients' Bill of Rights and Responsibilities Act (Hawaii Revised Statutes §432E-1.4), or for QUEST Integration members under Hawaii Administrative Rules (HAR 1700.1-42), generally accepted standards of medical practice and review of medical literature and government approval status. HMSA has determined that services not covered under this Medical Policy will not be medically necessary under Hawaii law in most cases. If a treating physician disagrees with HMSA's determination as to medical necessity in a given case, the physician may request that HMSA reconsider the application of the medical necessity criteria to the case at issue in light of any supporting documentation.

Genetic testing is covered for level 1 or 2A recommendations of the National Comprehensive Cancer Network (NCCN and in accordance with Hawaii's Patients' Bill of Rights and Responsibilities Act (Hawaii Revised Statutes §432E-1.4) or for QUEST members, the Hawaii Administrative Rules (HAR 1700.1-42).

VIII. Evidence-based Scientific References

- ACOG. (2017). Committee Opinion No. 691: Carrier Screening for Genetic Conditions. *Obstet Gynecol*, 129(3), e41-e55. <https://doi.org/10.1097/aog.0000000000001952>
- Antar, L. N., Li, C., Zhang, H., Carroll, R. C., & Bassell, G. J. (2006). Local functions for FMRP in axon growth cone motility and activity-dependent regulation of filopodia and spine synapses. *Mol Cell Neurosci*, 32(1-2), 37-48. <https://doi.org/10.1016/j.mcn.2006.02.001>
- Ascano, M., Jr., Mukherjee, N., Bandaru, P., Miller, J. B., Nusbaum, J. D., Corcoran, D. L., Langlois, C., Munschauer, M., Dewell, S., Hafner, M., Williams, Z., Ohler, U., & Tuschl, T. (2012). FMRP targets distinct mRNA sequence elements to regulate protein expression. *Nature*, 492(7429), 382-386. <https://doi.org/10.1038/nature11737>
- Bailey, D. B., Jr., Skinner, D., & Sparkman, K. L. (2003). Discovering fragile X syndrome: family experiences and perceptions. *Pediatrics*, 111(2), 407-416. <https://www.ncbi.nlm.nih.gov/pubmed/12563071>
- Bear, M. F., Huber, K. M., & Warren, S. T. (2004). The mGluR theory of fragile X mental retardation. *Trends Neurosci*, 27(7), 370-377. <https://doi.org/10.1016/j.tins.2004.04.009>
- Bechara, E. G., Didiot, M. C., Melko, M., Davidovic, L., Bensaid, M., Martin, P., Castets, M., Pognonec, P., Khandjian, E. W., Moine, H., & Bardoni, B. (2009). A novel function for fragile X mental retardation protein in translational activation. *PLoS Biol*, 7(1), e16. <https://doi.org/10.1371/journal.pbio.1000016>
- Biancalana, V., Glaeser, D., McQuaid, S., & Steinbach, P. (2015). EMQN best practice guidelines for the molecular genetic testing and reporting of fragile X syndrome and other fragile X-associated disorders. *Eur J Hum Genet*, 23(4), 417-425. <https://doi.org/10.1038/ejhg.2014.185>
- Cai, X., Arif, M., Wan, H., Kornreich, R., & Edelmann, L. J. (2019). Clinical Genetic Testing for Fragile X Syndrome by Polymerase Chain Reaction Amplification and Southern Blot Analyses. *Methods Mol Biol*, 1942, 11-27. https://doi.org/10.1007/978-1-4939-9080-1_2
- Cao, Q., Mu, W., Sun, D., Zhu, J., Ge, J., Peng, Y., & Zhang, J. (2021). [Significance and case analysis of FMR1 mutation screening during early and middle pregnancy]. *Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics*, 38(5), 450-453. <https://doi.org/10.3760/cma.j.cn511374-20200319-00181>
- Castagnola, S., Delhay, S., Folci, A., Paquet, A., Brau, F., Duprat, F., Jarjat, M., Grossi, M., Beal, M., Martin, S., Mantegazza, M., Bardoni, B., & Maurin, T. (2018). New Insights Into the Role of Cav2 Protein Family in Calcium Flux Deregulation in Fmr1-KO Neurons. *Front Mol Neurosci*, 11, 342. <https://doi.org/10.3389/fnmol.2018.00342>
- Chen, L., Hadd, A., Sah, S., Filipovic-Sadic, S., Krosting, J., Sekinger, E., Pan, R., Hagerman, P. J., Stenzel, T. T., Tassone, F., & Latham, G. J. (2010). An information-rich CGG repeat primed PCR that detects the full range of fragile X expanded alleles and minimizes the need for southern blot analysis. *J Mol Diagn*, 12(5), 589-600. <https://doi.org/10.2353/jmoldx.2010.090227>
- Coffee, B., Keith, K., Albizua, I., Malone, T., Mowrey, J., Sherman, S. L., & Warren, S. T. (2009). Incidence of fragile X syndrome by newborn screening for methylated FMR1 DNA. *Am J Hum Genet*, 85(4), 503-514. <https://doi.org/10.1016/j.ajhg.2009.09.007>
- Didiot, M. C., Tian, Z., Schaeffer, C., Subramanian, M., Mandel, J. L., & Moine, H. (2008). The G-quartet containing FMRP binding site in FMR1 mRNA is a potent exonic splicing enhancer. *Nucleic Acids Res*, 36(15), 4902-4912. <https://doi.org/10.1093/nar/gkn472>
- Finucane, B., Abrams, L., Cronister, A., Archibald, A. D., Bennett, R. L., & McConkie-Rosell, A. (2012). Genetic counseling and testing for FMR1 gene mutations: practice guidelines of the national society of genetic counselors. *J Genet Couns*, 21(6), 752-760. <https://doi.org/10.1007/s10897-012-9524-8>

- Garcia-Arocena, D., & Hagerman, P. J. (2010). Advances in understanding the molecular basis of FXTAS. *Hum Mol Genet*, 19(R1), R83-89. <https://doi.org/10.1093/hmg/ddq166>
- Gregg, A. R., Aarabi, M., Klugman, S., Leach, N. T., Bashford, M. T., Goldwaser, T., Chen, E., Sparks, T. N., Reddi, H. V., Rajkovic, A., Dungan, J. S., Practice, A. P., & Guidelines, C. (2021). Screening for autosomal recessive and X-linked conditions during pregnancy and preconception: a practice resource of the American College of Medical Genetics and Genomics (ACMG). *Genet Med*, 23(10), 1793-1806. <https://doi.org/10.1038/s41436-021-01203-z>
- Hagerman, R., & Hagerman, P. (2013). Advances in clinical and molecular understanding of the FMR1 premutation and fragile X-associated tremor/ataxia syndrome. *Lancet Neurol*, 12(8), 786-798. [https://doi.org/10.1016/S1474-4422\(13\)70125-X](https://doi.org/10.1016/S1474-4422(13)70125-X)
- Handt, M., Epplen, A., Hoffjan, S., Mese, K., Epplen, J. T., & Dekomien, G. (2014). Point mutation frequency in the FMR1 gene as revealed by fragile X syndrome screening. *Mol Cell Probes*, 28(5-6), 279-283. <https://doi.org/10.1016/j.mcp.2014.08.003>
- Hersh, J. H., & Saul, R. A. (2011). Health supervision for children with fragile X syndrome. *Pediatrics*, 127(5), 994-1006. <https://doi.org/10.1542/peds.2010-3500>
- Huang, W., Xue, J., Kang, H., Guan, X., Teng, Y., Wu, L., & Duan, R. (2019). [Prenatal diagnosis for 30 women carrying a FMR1 mutation]. *Zhonghua Yi Xue Yi Chuan Xue Za Zhi*, 36(9), 866-869. <https://doi.org/10.3760/cma.j.issn.1003-9406.2019.09.003>
- Jin, P., & Warren, S. T. (2000). Understanding the molecular basis of fragile X syndrome. *Hum Mol Genet*, 9(6), 901-908. <https://www.ncbi.nlm.nih.gov/pubmed/10767313>
- Johnson, K., Herring, J., & Richstein, J. (2020). Fragile X Premutation Associated Conditions (FXPAC). *Front Pediatr*, 8, 266. <https://doi.org/10.3389/fped.2020.00266>
- Kenny, P. J., Zhou, H., Kim, M., Skariah, G., Khetani, R. S., Drnevich, J., Arcila, M. L., Kosik, K. S., & Ceman, S. (2014). MOV10 and FMRP regulate AGO2 association with microRNA recognition elements. *Cell Rep*, 9(5), 1729-1741. <https://doi.org/10.1016/j.celrep.2014.10.054>
- Kronquist, K. E., Sherman, S. L., & Spector, E. B. (2008). Clinical significance of tri-nucleotide repeats in Fragile X testing: a clarification of American College of Medical Genetics guidelines. *Genet Med*, 10(11), 845-847. <https://doi.org/10.1097/GIM.0b013e31818b0c8a>
- Lee, S., Taylor, J. L., Redmond, C., Hadd, A. G., Kemppainen, J. A., Haynes, B. C., Shone, S., Bailey, D. B., Jr., & Latham, G. J. (2020). Validation of Fragile X Screening in the Newborn Population Using a Fit-for-Purpose FMR1 PCR Assay System. *J Mol Diagn*, 22(3), 346-354. <https://doi.org/10.1016/j.jmoldx.2019.11.002>
- Lim, G. X., Yeo, M., Koh, Y. Y., Winarni, T. I., Rajan-Babu, I. S., Chong, S. S., Faradz, S. M., & Guan, M. (2017). Validation of a commercially available test that enables the quantification of the numbers of CGG trinucleotide repeat expansion in FMR1 gene. *PLoS One*, 12(3), e0173279. <https://doi.org/10.1371/journal.pone.0173279>
- Lyon, E., Laver, T., Yu, P., Jama, M., Young, K., Zoccoli, M., & Marlowe, N. (2010). A simple, high-throughput assay for Fragile X expanded alleles using triple repeat primed PCR and capillary electrophoresis. *J Mol Diagn*, 12(4), 505-511. <https://doi.org/10.2353/jmoldx.2010.090229>
- Maurin, T., Zongaro, S., & Bardoni, B. (2014). Fragile X Syndrome: from molecular pathology to therapy. *Neurosci Biobehav Rev*, 46 Pt 2, 242-255. <https://doi.org/10.1016/j.neubiorev.2014.01.006>
- Mila, M., Rodriguez-Revenga, L., & Matilla-Duenas, A. (2016). FMR1 Premutation: Basic Mechanisms and Clinical Involvement. *Cerebellum*, 15(5), 543-545. <https://doi.org/10.1007/s12311-016-0808-7>
- Monaghan, K. G., Lyon, E., Spector, E. B., & American College of Medical, G. a. G. (2013). ACMG Standards and Guidelines for fragile X testing: a revision to the disease-specific supplements to the Standards and Guidelines for Clinical Genetics Laboratories of the American College of

- Medical Genetics and Genomics. *Genet Med*, 15(7), 575-586.
<https://doi.org/10.1038/gim.2013.61>
- Napoli, E., Schneider, A., Wang, J. Y., Trivedi, A., Carrillo, N. R., Tassone, F., Rogawski, M., Hagerman, R. J., & Giulivi, C. (2018). Allopregnanolone Treatment Improves Plasma Metabolomic Profile Associated with GABA Metabolism in Fragile X-Associated Tremor/Ataxia Syndrome: a Pilot Study. *Mol Neurobiol*. <https://doi.org/10.1007/s12035-018-1330-3>
- NORD. (2017). Fragile X Syndrome. <https://rarediseases.org/rare-diseases/fragile-x-syndrome/>
- Oberle, I., Rousseau, F., Heitz, D., Kretz, C., Devys, D., Hanauer, A., Boue, J., Bertheas, M. F., & Mandel, J. L. (1991). Instability of a 550-base pair DNA segment and abnormal methylation in fragile X syndrome. *Science*, 252(5009), 1097-1102. <https://www.ncbi.nlm.nih.gov/pubmed/2031184>
- Oostra, B. A., & Willemsen, R. (2001). Diagnostic tests for fragile X syndrome. *Expert Rev Mol Diagn*, 1(2), 226-232. <https://doi.org/10.1586/14737159.1.2.226>
- Ormazabal, M., Solari, A., Espeche, L., Castro, T., & Buzzalino, N. (2019). [Fragile X syndrome and other entities associated with the FMR1 gene: Study of 28 affected families]. *Arch Argent Pediatr*, 117(3), e257-e262. <https://doi.org/10.5546/aap.2019.e257> (Fragilidad del X y otras entidades asociadas al gen FMR1: estudio de 28 familias afectadas.)
- Parvin, S., Takeda, R., Sugiura, Y., Neyazaki, M., Nogi, T., & Sasaki, Y. (2018). Fragile X mental retardation protein regulates accumulation of the active zone protein Munc18-1 in presynapses via local translation in axons during synaptogenesis. *Neurosci Res*.
<https://doi.org/10.1016/j.neures.2018.09.013>
- Peprah, E. (2012). Fragile X syndrome: the FMR1 CGG repeat distribution among world populations. *Ann Hum Genet*, 76(2), 178-191. <https://doi.org/10.1111/j.1469-1809.2011.00694.x>
- Rais, M., Binder, D. K., Razak, K. A., & Ethell, I. M. (2018). Sensory Processing Phenotypes in Fragile X Syndrome. *ASN Neuro*, 10, 1759091418801092. <https://doi.org/10.1177/1759091418801092>
- Rajan-Babu, I. S., & Chong, S. S. (2016). Molecular Correlates and Recent Advancements in the Diagnosis and Screening of FMR1-Related Disorders. *Genes (Basel)*, 7(10).
<https://doi.org/10.3390/genes7100087>
- Rajan-Babu, I. S., Teo, C. R., Lian, M., Lee, C. G., Law, H. Y., & Chong, S. S. (2015). Single-tube methylation-specific duplex-PCR assay for rapid and accurate diagnosis of Fragile X Mental Retardation 1-related disorders. *Expert Rev Mol Diagn*, 15(3), 431-441.
<https://doi.org/10.1586/14737159.2015.1001749>
- Ramos, C., Ocampos, M., Barbato, I. T., Graça Bicalho, M. d., & Nishihara, R. (2020). Molecular analysis of FMR1 gene in a population in Southern Brazil: Comparison of four methods. *Practical Laboratory Medicine*, 21, e00162.
<https://doi.org/https://doi.org/10.1016/j.plabm.2020.e00162>
- Ramos, C., Ocampos, M., Barbato, I. T., Niehues, V. M. S., Bicalho, M. D. G., & Nishihara, R. (2021). Association between mutations in the FMR1 gene and ovarian dysfunction in Brazilian patients. *JBRA Assist Reprod*. <https://doi.org/10.5935/1518-0557.20210063>
- Raspa, M., Wylie, A., Wheeler, A. C., Kolacz, J., Edwards, A., Heilman, K., & Porges, S. W. (2018). Sensory Difficulties in Children With an FMR1 Premutation. *Front Genet*, 9, 351.
<https://doi.org/10.3389/fgene.2018.00351>
- Reisinger, D. L., Shaffer, R. C., Tartaglia, N., Berry-Kravis, E., & Erickson, C. A. (2020). Delineating Repetitive Behavior Profiles across the Lifespan in Fragile X Syndrome. *Brain Sci*, 10(4).
<https://doi.org/10.3390/brainsci10040239>
- Riley, C., & Wheeler, A. (2017). Assessing the Fragile X Syndrome Newborn Screening Landscape. *Pediatrics*, 139(Suppl 3), S207-S215. <https://doi.org/10.1542/peds.2016-1159G>

- Rosario, R., & Anderson, R. (2020). The molecular mechanisms that underlie fragile X-associated premature ovarian insufficiency: is it RNA or protein based? *Molecular Human Reproduction*. <https://doi.org/10.1093/molehr/gaaa057>
- Santoro, M. R., Bray, S. M., & Warren, S. T. (2012). Molecular mechanisms of fragile X syndrome: a twenty-year perspective. *Annu Rev Pathol*, 7, 219-245. <https://doi.org/10.1146/annurev-pathol-011811-132457>
- Saul, R. A., & Tarleton, J. C. (1993). FMR1-Related Disorders. In M. P. Adam, H. H. Ardinger, R. A. Pagon, S. E. Wallace, L. J. H. Bean, K. Stephens, & A. Amemiya (Eds.), *GeneReviews*((R)). <https://www.ncbi.nlm.nih.gov/pubmed/20301558>
- Sherman, S., Pletcher, B. A., & Driscoll, D. A. (2005). Fragile X syndrome: diagnostic and carrier testing. *Genet Med*, 7(8), 584-587. <https://doi.org/10.109701.GIM.0000182468.22666.dd>
- Sitzmann, A. F., Hagelstrom, R. T., Tassone, F., Hagerman, R. J., & Butler, M. G. (2018). Rare FMR1 gene mutations causing fragile X syndrome: A review. *Am J Med Genet A*, 176(1), 11-18. <https://doi.org/10.1002/ajmg.a.38504>
- Skrlec, I., Barisic, K., & Wagner, J. (2018). Validation of a Screening Method for Dynamic Mutations in the FMR1 Gene. *Ann Clin Lab Sci*, 48(6), 810-813. <https://www.ncbi.nlm.nih.gov/pubmed/30610057>
- Suhl, J. A., & Warren, S. T. (2015). Single-Nucleotide Mutations in FMR1 Reveal Novel Functions and Regulatory Mechanisms of the Fragile X Syndrome Protein FMRP. *J Exp Neurosci*, 9(Suppl 2), 35-41. <https://doi.org/10.4137/JEN.S25524>
- Tassone, F., Hagerman, R. J., Taylor, A. K., Gane, L. W., Godfrey, T. E., & Hagerman, P. J. (2000). Elevated levels of FMR1 mRNA in carrier males: a new mechanism of involvement in the fragile-X syndrome. *Am J Hum Genet*, 66(1), 6-15. <https://doi.org/10.1086/302720>
- Tekcan, A. (2016). In Silico Analysis of FMR1 Gene Missense SNPs. *Cell Biochem Biophys*, 74(2), 109-127. <https://doi.org/10.1007/s12013-016-0722-0>
- Teo, C. R., Law, H. Y., Lee, C. G., & Chong, S. S. (2012). Screening for CGG repeat expansion in the FMR1 gene by melting curve analysis of combined 5' and 3' direct triplet-primed PCRs. *Clin Chem*, 58(3), 568-579. <https://doi.org/10.1373/clinchem.2011.174615>
- Willemsen, R., Bontekoe, C. J., Severijnen, L. A., & Oostra, B. A. (2002). Timing of the absence of FMR1 expression in full mutation chorionic villi. *Hum Genet*, 110(6), 601-605. <https://doi.org/10.1007/s00439-002-0723-5>
- Wilson, Bie, Armour, Brown, Campagnolo, Carroll, R. C., Okun, Nelson, & Zwingerman. (2016). Joint SOGC-CCMG Opinion for Reproductive Genetic Carrier Screening: An Update for All Canadian Providers of Maternity and Reproductive Healthcare in the Era of Direct-to-Consumer Testing. *Journal of Obstetrics and Gynaecology Canada*, 38(8), 742-762. [https://www.jogc.com/article/S1701-2163\(16\)39347-1/fulltext](https://www.jogc.com/article/S1701-2163(16)39347-1/fulltext)
- Yang, Y. M., Arsenault, J., Bah, A., Krzeminski, M., Fekete, A., Chao, O. Y., Pacey, L. K., Wang, A., Forman-Kay, J., Hampson, D. R., & Wang, L. Y. (2018). Identification of a molecular locus for normalizing dysregulated GABA release from interneurons in the Fragile X brain. *Mol Psychiatry*. <https://doi.org/10.1038/s41380-018-0240-0>
- Yu, S., Pritchard, M., Kremer, E., Lynch, M., Nancarrow, J., Baker, E., Holman, K., Mulley, J. C., Warren, S. T., Schlessinger, D., & et al. (1991). Fragile X genotype characterized by an unstable region of DNA. *Science*, 252(5009), 1179-1181. <https://www.ncbi.nlm.nih.gov/pubmed/2031189>
- Zafarullah, M., Tang, H.-T., Durbin-Johnson, B., Fourie, E., Hessel, D., Rivera, S. M., & Tassone, F. (2020). FMR1 locus isoforms: potential biomarker candidates in fragile X-associated tremor/ataxia syndrome (FXTAS). *Scientific Reports*, 10(1), 11099. <https://doi.org/10.1038/s41598-020-67946-y>

IX. Policy History

Policy approved by Medical Directors	9/20/2022
Policy approved at UMC	12/16/2022
Policy effective	6/1/2023
Updated Lines of Business	12/18/2023